Dr Matthew Bull
BSc MSc PhD Auck.
Dr Matthew Bull
Dr Matthew Bull
https://unidirectory.auckland.ac.nz/profile/m-bullResearch Fellow The University of Auckland: Auckland Cancer Research Centre
Postdoctoral research fellow at the Auckland Cancer Society Research Centre with the Translational Therapeutics Team, led by Associate Professor Adam Patterson.
Research | Current
- Ongoing development of TH-4000, a hypoxia-selective tyrosine kinase inhibitor (TKI) curently in Phase 2 clincial trials for lung cancer and Head/Neck cancer in USA and Australia
- Development of additional hypoxia-selective TKI prodrugs
- Development of the hypoxia-selective analogues of the prodrug PR-104
Areas of expertise
- In vitro metabolism
- Bioanalysis (HPLC, LC/MS/MS, SPR etc)
- Hypoxia activated prodrugs
- Cancer drug development
Selected publications and creative works (Research Outputs)
- Bull, M. R., Spicer, J. A., Huttunen, K. M., Denny, W. A., Ciccone, A., Browne, K. A., ... Helsby, N. A. (2015). The preclinical pharmacokinetic disposition of a series of perforin-inhibitors as potential immunosuppressive agents. European journal of drug metabolism and pharmacokinetics, 40 (4), 417-425. 10.1007/s13318-014-0220-y
Other University of Auckland co-authors: Bill Denny, Julie Spicer, Nuala Helsby
- Silva, S., Jackson, V., Guise, C., Abbattista, M., Bull, M., Grey, A. C., ... Pearce, T. (2015). Preclinical Efficacy of Tarloxotinib Bromide (TH-4000), a Hypoxia-Activated EGFR/HER2 Inhibitor: Rationale for Clinical Evaluation in EGFR Mutant, T790M-Negative NSCLC Following Progression on EGFR-TKI Therapy. Paper presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts. 5 November - 9 November 2015.
Other University of Auckland co-authors: Gus Grey, Maria Abbattista, Christopher Guise, Bob Anderson, Amir Ashoorzadeh, Adam Patterson, Jeffrey Smaill, Victoria Jackson-Patel
- Patterson, A. V., Silva, S., Guise, C., Abbattista, M., Bull, M., Hsu, H.-L., ... Ashoorzadeh, A. (2015). Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial. Cancer Research. 10.1158/1538-7445.AM2015-5358
Other University of Auckland co-authors: Gus Grey, Adam Patterson, Christopher Guise, Maria Abbattista, Amir Ashoorzadeh, Bob Anderson, Jeffrey Smaill
- Patterson, A. V., Silva, S., Guise, C., Bull, M., Abbattista, M., Hsu, A., ... Smaill, J. B. (2015). TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC. Paper presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL. 29 May - 2 June 2015. JOURNAL OF CLINICAL ONCOLOGY. (pp. 1).
Other University of Auckland co-authors: Christopher Guise, Jeffrey Smaill, Adam Patterson, Maria Abbattista
- Patterson, A., Silva, S., Jackson, V., Guise, C., Abbattista, M. R., Bull, M., ... Jung, D. (2015). The Hypoxia-Activated EGFR-TKI TH-4000: Preclinical Profile and Ongoing Clinical Studies in NSCLC, SCCHN, and SCCS. Paper presented at 14th International Tumor Microenvironment Workshop: Hypoxia, Angiogensis and Vasculature, Vancouver, Canada. 27 August - 29 August 2015.
Other University of Auckland co-authors: Maria Abbattista, Adam Patterson, Christopher Guise, Amir Ashoorzadeh, Bob Anderson, Jeffrey Smaill, Gus Grey
- Jackson, V., Silva, S., Abbattista, M., Guise, C., Bull, M., Ashoorzadeh, A., ... Patterson, A. (1/1/2015). Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).. Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts. Related URL.
Other University of Auckland co-authors: Maria Abbattista, Christopher Guise, Amir Ashoorzadeh, Adam Patterson, Jeffrey Smaill
- Spicer, J. A., Lena, G., Lyons, D. M., Huttunen, K. M., Miller, C. K., O'Connor PD, ... Denny, W. A. (2013). Exploration of a series of 5-arylidene-2-thioxoimidazolidin-4-ones as inhibitors of the cytolytic protein perforin. Journal of medicinal chemistry, 56 (23), 9542-9555. 10.1021/jm401604x
Other University of Auckland co-authors: Nuala Helsby, Christian Miller, Bill Denny, Julie Spicer, Stephen Jamieson
- Bull, M. R. (2013). The preclinical pharmacology of novel inhibitors of perforin function The University of Auckland. ResearchSpace@Auckland.